Search

Your search keyword '"Scherzer, Clemens R."' showing total 404 results

Search Constraints

Start Over You searched for: Author "Scherzer, Clemens R." Remove constraint Author: "Scherzer, Clemens R."
404 results on '"Scherzer, Clemens R."'

Search Results

1. Investigation of the genetic aetiology of Lewy body diseases with and without dementia

3. Clinical Trial-Ready Patient Cohorts for Multiple System Atrophy: Coupling Biospecimen and iPSC Banking to Longitudinal Deep-Phenotyping

4. Genetic evaluation of dementia with Lewy bodies implicates distinct disease subgroups.

5. Correction to: Clinical trial-ready patient cohorts for multiple system atrophy: coupling biospecimen and iPSC banking to longitudinal deep-phenotyping

6. Differential blood DNA methylation across Lewy body dementias

9. Genome-wide structural variant analysis identifies risk loci for non-Alzheimer’s dementias

13. β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson’s disease

14. Pathogenic Huntingtin Repeat Expansions in Patients with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis

15. Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinson’s disease

16. Age-associated insolubility of parkin in human midbrain is linked to redox balance and sequestration of reactive dopamine metabolites

17. Prediction of cognition in Parkinson's disease with a clinical–genetic score: a longitudinal analysis of nine cohorts

18. Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture

20. A systems-biology approach connects aging mechanisms with Alzheimer’s disease pathogenesis

21. Deep sequencing of proteotoxicity modifier genes uncovers a Presenilin-2/beta-amyloid-actin genetic risk module shared among alpha-synucleinopathies

22. Venglustat in GBA1-related Parkinson's disease – Authors' reply

27. β-Glucocerebrosidase activity in GBA-linked Parkinson disease: The type of mutation matters

29. Genetic risk of Parkinson disease and progression: An analysis of 13 longitudinal cohorts

30. Publisher Correction: Enhancers active in dopamine neurons are a primary link between genetic variation and neuropsychiatric disease

31. Enhancers active in dopamine neurons are a primary link between genetic variation and neuropsychiatric disease

32. Mitochondrial haplogroups and cognitive progression in Parkinson's disease

33. Genome-wide structural variant analysis identifies risk loci for non-Alzheimer’s dementias

35. Genome-wide structural variant analysis identifies risk loci for non-Alzheimer’s dementias

37. Plasma biomarkers for diagnosis of Alzheimer's disease and prediction of cognitive decline in individuals with mild cognitive impairment

39. Correction to: Clinical trial-ready patient cohorts for multiple system atrophy: coupling biospecimen and iPSC banking to longitudinal deep-phenotyping

40. Clinical Trial-Ready Patient Cohorts for Multiple System Atrophy: Coupling Biospecimen and iPSC Banking to Longitudinal Deep-Phenotyping

42. <scp> GBA </scp> and <scp> APOE </scp> Impact Cognitive Decline in Parkinson's Disease: A 10‐Year Population‐Based Study

44. GBA and APOE impact cognitive decline in Parkinson's disease : A 10-year population-based study

45. Proteome profiling of cerebrospinal fluid reveals biomarker candidates for Parkinson's disease

48. Plasma biomarkers for prognosis of cognitive decline in patients with mild cognitive impairment

50. Plasma biomarkers for diagnosis of Alzheimer's disease and prediction of cognitive decline in individuals with mild cognitive impairment

Catalog

Books, media, physical & digital resources